Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz effect on Ganaplacide and Lumefantrine PK
NCT05330273Phase 1Completed
- Sponsor
- Novartis
- Start
- Apr 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ganaplacide and lumefantrine in malaria, sponsored by Novartis. Primary endpoints: Observed maximum plasma concentration, Area under the serum concentration-time curve to last quantifiable concentration and 6 more. Started Apr 2022; status: completed.
02
Drugs
ganaplacidelumefantrine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05330273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330273.